• Efficacy and Safety of Azilsartan Medoxomil in Hypertension:

  2026-06-03

  This systematic review and meta-analysis rigorously evaluates azilsartan medoxomil’s efficacy and safety for hypertension, including patients with diabetes. The findings position TAK 491 as one of the most effective angiotensin II receptor blockers for blood pressure reduction, with no increased risk of adverse events compared to controls.

• CBD Modulates Orofacial Inflammatory Pain via Multi-Domain M

  2026-06-03

  This study demonstrates that cannabidiol (CBD) effectively attenuates both the sensory and emotional components of orofacial inflammatory pain in murine models. By dissecting the peripheral and central pathways—including CB1 and CB2 receptor signaling—the research highlights CBD's translational potential for comprehensive pain management and supports the need for targeted molecular tools in pain mechanism studies.

• Verapamil HCl: L-Type Calcium Channel Blocker in Bone & Canc

  2026-06-02

  Verapamil HCl is a well-characterized L-type calcium channel blocker with robust solubility and validated efficacy in inhibiting calcium influx, thereby modulating cellular excitability and apoptosis. Its bench-to-model translational value spans from myeloma cell research to attenuation of arthritis inflammation and suppression of osteoporosis-related bone turnover, as supported by recent peer-reviewed studies.

• Otilonium Bromide: Antimuscarinic Agent for Cholinergic Rese

  2026-06-02

  Otilonium Bromide is a high-purity antimuscarinic agent used to inhibit acetylcholine receptors in neuroscience and smooth muscle research. Its robust solubility and validated specificity enable precise modulation of the cholinergic signaling pathway. This article details its biological rationale, documented mechanisms, application limits, and protocol integration.

• E-4031 and the Next Era of 3D Cardiac Electrophysiology

  2026-06-01

  Explore how E-4031, a gold-standard hERG potassium channel blocker, is redefining translational strategies in 3D cardiac electrophysiology research. This article unpacks mechanistic insights, protocol guidance, and the transformative impact of high-resolution 3D mapping platforms—empowering researchers to model arrhythmogenic risk with unprecedented fidelity.

• Vernakalant Hydrochloride: Unpacking PK/PD for Precision AF

  2026-06-01

  Explore Vernakalant Hydrochloride's pharmacokinetics and pharmacodynamics in depth, including its unique atrial-selective actions for rapid conversion of atrial fibrillation. This article reveals key insights for advanced assay design and clinical translation.

• Quercetin as a PI3K Inhibitor: Mechanistic Leverage for Tran

  2026-05-31

  This article provides a thought-leadership perspective for translational researchers on leveraging Quercetin, a potent PI3K inhibitor, in experimental workflows. Integrating recent mechanistic discoveries—particularly its dual action on apoptosis and ferroptosis—this piece bridges molecular insight with practical strategy, offering advanced guidance for those aiming to exploit Quercetin’s multi-targeted effects in cancer and liver disease models. The discussion highlights protocol considerations, competitive positioning, and strategic outlook, with evidence-based recommendations and contextual product insights from APExBIO.

• Multi-Omics Reveals ARID1A-Driven Resistance to Vemurafenib

  2026-05-30

  This study applies integrative multi-omics to dissect drug resistance networks in BRAF-mutant melanoma, identifying ARID1A loss as a key driver of sustained MAPK signaling and immune evasion under BRAF/MAPK inhibitor treatment. The findings highlight actionable resistance nodes and inform strategies for overcoming therapeutic failure in metastatic melanoma.

• 3D Electrophysiological Mapping of Cardiac Organoids with Sh

  2026-05-29

  This study introduces shell microelectrode arrays enabling true 3D, high-resolution electrophysiological mapping of cardiac organoids. The platform allows detailed analysis of conduction dynamics, arrhythmogenic risk, and pharmacological response—advancing the modeling of human cardiac disease and drug safety.

• Ellagic Acid in Cancer Biology: Protocols and Senolytic Inno

  2026-05-29

  Ellagic acid's selective ATP-competitive CK2 inhibition enables precise cancer biology and oxidative stress research. This article delivers actionable protocols, AI-driven assay enhancements, and troubleshooting guidance for advanced experimental workflows.

• hiPSC-Derived Intestinal Organoids Advance Pharmacokinetic S

  2026-05-28

  This paper presents a streamlined protocol to generate human pluripotent stem cell-derived intestinal organoids with robust self-renewal and differentiation potential. The resulting organoid-derived epithelial cells provide a more physiologically relevant in vitro model for pharmacokinetic research, particularly for studying drug absorption and metabolism in the human intestine.

• 2-APB in Calcium Signaling Research: Protocols and Innovatio

  2026-05-28

  2-APB (2-aminoethoxydiphenyl borate) empowers precision dissection of calcium-dependent autophagy and apoptosis, as demonstrated in recent ER-Ca2+-calpain pathway studies. This guide translates new mechanistic insights and peer protocols into actionable workflows and troubleshooting strategies for advanced cell fate research.

• Structural Insights into ω-Agatoxin IVA Sensitivity in Cav2.

  2026-05-27

  This study reveals the molecular basis for the differential sensitivity of P-type and Q-type Cav2.1 channels to ω-agatoxin IVA, using high-resolution cryo-EM structures. The findings clarify how specific extracellular loop variations determine toxin binding, with direct implications for synaptic transmission research and the development of targeted neurotherapeutics.

• Azilsartan Medoxomil Monopotassium: Advanced Workflows in Hy

  2026-05-27

  Azilsartan medoxomil monopotassium (TAK 491) stands apart for its unparalleled AT1 receptor affinity and sustained antagonistic action, making it a premier tool for essential hypertension treatment research. This guide delivers actionable protocols, experimental enhancements, and troubleshooting strategies that empower cardiovascular and renal studies to achieve reproducible, high-fidelity results.

• Ranolazine: Anti-Ischemic Agent Mechanisms and Research Benc

  2026-05-26

  Ranolazine is a validated anti-ischemic agent that inhibits the late sodium current in cardiac cells, reduces sodium-dependent calcium overload, and shifts cellular ATP production toward glucose oxidation. These properties confer improved myocardial relaxation and metabolic efficiency, as confirmed in peer-reviewed and product literature. Ranolazine is supplied by APExBIO at ≥99.21% purity for research use.

11450 records 1/764 page Next 12345 下5页 Last page